Business Wire

Creative Visionary Nicola Formichetti Named Global Creative Director, M·A·C Cosmetics

Share

The Estée Lauder Companies (NYSE:EL) and M·A·C Cosmetics announced today the appointment of Nicola Formichetti as Global Creative Director, effective May 19, 2025. A celebrated creative director, designer, and cultural icon, Formichetti brings his visionary artistry, genre-defying creativity and consumer-first mindset to the helm of M·A·C’s global creative strategy. He will report directly to Aïda Moudachirou-Rébois, M·A·C’s Senior Vice President and Global General Manager.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514389264/en/

Photograph by Matthew Brookes

Formichetti’s appointment marks a pivotal moment for M·A·C as the brand continues to shape the future of beauty through boundary-pushing innovation and cultural relevance. His dynamic approach to creativity, rooted at the intersection of fashion, music, culture, and technology, will spark new levels of desirability for M·A·C, driving its product innovation, creative collaborations, and global consumer engagement. In his new role, Formichetti will shape the strategy, conceptualization and execution of M·A·C’s creative vision, elevating the brand’s global image and impact across every touchpoint – from campaigns and social media platforms to product, packaging, and immersive retail experiences. At its core, M·A·C is built on artistry – and as an artist and visionary himself, Formichetti will play a central role in reimagining what artistry means for the next generation of consumers. He will lead a multidisciplinary creative team, building on the brand’s iconic heritage in artistry, trendsetting, limitless self-expression and individuality to deliver bold storytelling that leaves a lasting impression on a global scale.

“Nicola is a once-in-a-generation creative talent who perfectly embodies the bold, fearless energy of M·A·C and our global community,” said Aïda Moudachirou-Rébois. “Like our consumers, Nicola is passionate, expressive and knows how to push boundaries. His appointment is not only a celebration of artistry, but a reflection of our commitment to serving our consumers with of-the-moment relevance, creativity and authenticity. He is the perfect Creative Director to drive the brand into its next exciting chapter.”

Renowned for his genre-defying work with global superstars like Lady Gaga, his creative oversight of some of fashion’s most influential houses, and his reputation for trend-defining collaborations, Formichetti is uniquely equipped to help M·A·C deliver on its mission to be a brand for “All Ages, All Races, All Genders.” Drawing from his Japanese and Italian heritage, he brings a globally attuned perspective that resonates deeply with M·A·C’s inclusive ethos. His forward-thinking approach seamlessly integrates technology and digital innovation, pushing creative boundaries and redefining how beauty and fashion engage with global audiences.

“Nicola’s appointment is a bold step forward for M·A·C and for The Estée Lauder Companies,” said Jane Hertzmark Hudis, Executive Vice President, Chief Brand Officer, The Estée Lauder Companies. “Nicola brings the vision, bold creativity and track record to take the M·A·C brand to new heights as it enters its next phase of growth. We are thrilled to bring this level of high-caliber creative talent to The Estée Lauder Companies.”

“This appointment represents yet another definitive step forward for The Estée Lauder Companies as we execute our recently announced Beauty Reimagined vision, which is focused on becoming the most consumer-centric prestige beauty company in the world,” said Stéphane de La Faverie, President and CEO, The Estée Lauder Companies. “A key component of Beauty Reimagined is meeting consumers where they are, and with Nicola’s unique ability to capture the pulse of culture, he will help shape exciting and innovative products and experiences. M·A·C’s tremendous brand equity is most powerful when it evolves with the times—and Nicola will leverage his creative vision to inspire a new generation of connection, self-expression, and loyalty.”

“M·A·C is an iconic brand that has always championed the people and communities that move culture forward,” said Formichetti. “Having previously collaborated with the brand on my Nicopanda collection and the M·A·C VIVA GLAM campaign, I’m thrilled to return and bring my vision to this next chapter. The world is craving creativity, beauty, and connection—and I can’t wait to help bring that to life in a magical way.”

Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include those in the various quotations. Although the Company believes that its expectations are based on reasonable assumptions within the bounds of its knowledge of its business and operations, actual results may differ materially from the Company’s expectations. Factors that could cause actual results to differ from expectations include the ability to successfully implement its strategy, including the Company’s profit recovery and growth plan; successfully transition its leadership; and those other factors described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. The Company assumes no responsibility to update forward-looking statements made herein or otherwise.

About The Estée Lauder Companies
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN Beauty.

ELC-L
ELC-B

View source version on businesswire.com: https://www.businesswire.com/news/home/20250514389264/en/

Contacts

Media Relations:
Diederik Koenders
dkoenders@maccosmetics.com

Investor Relations:
Rainey Mancini
rmancini@estee.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye